4D MOLECULAR THERAPEUTICS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 24.46 USD | +5.18% |
|
-8.26% | +19.50% |
Chart calendar 4D Molecular Therapeutics, Inc.
316d212fd3c90c48bb355b81.twgT53mqSCiK8_Bs_lwnqfcf-K866uI4Ujw0LhfdSnQ.gl1jjSvEfFrShboKqzES9rR2yuhSiddnAFlHRmS-ej7Fb2qkN_kmYNqluQ~c2260d66ae0fab1551a3af72ed6bdc6f
Upcoming events on 4D Molecular Therapeutics, Inc.
Past events on 4D Molecular Therapeutics, Inc.
| 13/03/2024 12:30 | Barclays Global Healthcare Conference |
| 12/03/2024 15:20 | Leerink Partners Global Biopharma Conference |
| 29/02/2024 21:05 | Q4 2023 Earnings Release |
| 05/02/2024 13:00 | Phase 2 PRISM Clinical Trial Update Call |
| 03/02/2024 20:30 | Angiogenesis Exudation and Degeneration Conference |
| 28/11/2023 18:45 | Evercore ISI HealthCONx Conference |
| 09/11/2023 21:19 | Q3 2023 Earnings Release |
| 03/11/2023 21:30 | North American Cystic Fibrosis Conference |
| 02/11/2023 22:30 | North American Cystic Fibrosis Conference |
| 01/11/2023 20:30 | AEROW Phase 1/2 Clinical Trail Call |
| 10/10/2023 | Cell & Gene Meeting on the Mesa Conference |
| 02/10/2023 19:30 | Chardan Genetic Medicines Conference |
| 28/09/2023 17:40 | Cantor Global Healthcare Conference |
| 26/09/2023 13:30 | Jefferies Cell & Genetic Medicine Summit |
| 11/09/2023 17:00 | H.C. Wainwright Global Investment Conference |
| 09/08/2023 21:05 | Q2 2023 Earnings Release |
| 28/07/2023 | American Society of Retina Meeting |
| 12/06/2023 22:00 | Goldman Sachs Global Healthcare Conference |
| 09/06/2023 15:00 | Jefferies Global Healthcare Conference |
| 08/06/2023 16:00 | European Cystic Fibrosis Society Meeting |
Annual results
| Fiscal Period | December | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 13,6 15,2 -10.5% | 18,0 18,8 -4.21% | 3,13 4,41 -29.03% | 20,7 22,6 -8.38% | 6,35 |
|
EBITDA Million USD | Released Forecast Spread | -55,2 -52,1 -5.91% | -69,8 -71,9 2.85% | -108 -108 0.24% | -109 -109 0.73% | -164 |
|
EBIT Million USD | Released Forecast Spread | -56,7 -53,2 -6.44% | -71,3 -73,4 2.77% | -110 -110 -0.31% | -113 -111 -1.26% | -153 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | 0,00 0,00 - | 0,00 0,00 - | -107 -107 -0.64% | -101 -100 -0.51% | -148 |
|
Net income Million USD | Released Forecast Spread | -56,7 -50,0 -13.48% | -71,3 -71,7 0.47% | -107 -104 -2.95% | -101 -98,0 -2.9% | -151 |
|
EPS USD | Released Forecast Spread | -8,82 -1,89 -366.67% | -2,57 -2,55 -0.78% | -3,32 -3,20 -3.81% | -2,58 -2,54 -1.51% | -3,12 |
| Announcement Date | 25/03/21 | 28/03/22 | 15/03/23 | 29/02/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,09 1,35 -93.19% | 1,22 0,76 60.75% | 0,16 1,14 -85.81% | 0,50 1,17 -57.2% | 1,25 3,76 -66.81% | 0,30 1,29 -76.81% | 0,24 1,02 -76.52% | 20,2 9,22 119.15% | -0,02 2,40 -100.79% | 1,07 | 1,04 | 1,09 | 1,03 | 0,50 |
|
EBITDA Million USD | Released Forecast Spread | -24,4 -26,1 6.56% | -28,0 -28,0 -0.03% | -29,1 -30,7 5.14% | |||||||||||
|
EBIT Million USD | Released Forecast Spread | -24,8 -26,8 7.57% | -26,4 -27,1 2.47% | -28,4 -29,4 3.23% | -26,5 -31,1 14.79% | -28,7 -28,4 -1.21% | -30,1 -31,5 4.36% | -32,1 -31,5 -2.11% | -14,0 -28,7 51.28% | -36,7 -35,8 -2.43% | -37,5 | -39,5 | -41,4 | -43,9 | -46,0 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -28,1 -25,7 -9.35% | -25,7 -28,3 9.16% | -27,4 -26,7 -2.57% | -28,7 -29,4 2.28% | -29,6 -30,0 1.41% | -10,3 -29,4 65.1% | -32,3 -31,9 -1.07% | -34,8 | -36,1 | -37,5 | -39,8 | |||
|
Net income Million USD | Released Forecast Spread | -25,1 -25,4 1.33% | -26,3 -24,9 -5.89% | -28,1 -25,3 -11.03% | -25,7 -27,6 6.77% | -27,4 -24,3 -12.76% | -28,7 -28,1 -2.07% | -29,6 -29,4 -0.74% | -10,3 -26,3 60.98% | -32,3 -28,9 -11.6% | -35,0 | -36,4 | -38,1 | -41,7 | |
|
EPS USD | Released Forecast Spread | -0,85 -0,79 -7.59% | -0,82 -0,73 -13.1% | -0,87 -0,78 -12.02% | -0,79 -0,85 6.69% | -0,84 -0,75 -12.75% | -0,88 -0,88 -0.57% | -0,77 -0,76 -1.58% | -0,24 -0,61 60.76% | -0,77 -0,71 -8.71% | -0,74 | -0,76 | -0,79 | -0,82 | |
| Announcement Date | 28/03/22 | 12/05/22 | 11/08/22 | 08/11/22 | 15/03/23 | 10/05/23 | 09/08/23 | 09/11/23 | 29/02/24 | - | - | - | - | - |
| Today 21:05 | QIAGEN N.V.: Q1 2024 Earnings Release |
| 29/04/2024 | CRISPR THERAPEUTICS AG: Q1 2024 Earnings Release (Projected) |
| 30/04/2024 | DYNE THERAPEUTICS, INC.: Q1 2024 Earnings Release (Projected) |
| 30/04/2024 | PROTAGONIST THERAPEUTICS, INC.: Q1 2024 Earnings Release (Projected) |
| 30/04/2024 | EDITAS MEDICINE, INC.: Q1 2024 Earnings Release (Projected) |
| 30/04/2024 | AZENTA, INC.: Q2 2024 Earnings Release (Projected) |
| 01/05/2024 11:30 | UNITED THERAPEUTICS CORPORATION: Q1 2024 Earnings Release |
| 01/05/2024 11:30 | BIO-TECHNE CORPORATION: Q3 2024 Earnings Release |
| 01/05/2024 12:00 | ALKERMES PLC: Q1 2024 Earnings Release |
| 01/05/2024 | VIR BIOTECHNOLOGY, INC.: Q1 2024 Earnings Release |
Past sector events for 4D Molecular Therapeutics, Inc.
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- FDMT Stock
- Calendar 4D Molecular Therapeutics, Inc.
